Amidst Utrecht's Science Park, a hub of Dutch biotech innovation, NanoCell Therapeutics' story of growth takes shape. In an interview, Maurits Geerlings, NanoCell's President & CEO, details the strategic expansion of this U.S.-based company into the Netherlands, shedding light on the synergistic benefits of integrating into this dynamic and forward-thinking ecosystem.
NanoCell Therapeutics, a privately held biotechnology firm with offices in Pennsylvania, USA, and a significant new presence in Utrecht, the Netherlands, is leading a transformative approach in the cell and gene therapy arena with its advanced in vivo gene delivery technology. The company’s innovation lies in its cutting-edge non-viral, DNA-based gene therapy platform, which aims to bring novel treatments to the forefront of oncology and autoimmune disease management.
Maurits Geerlings, at the helm of NanoCell, explains the company’s dedication to harnessing genetic strategies to empower the immune system to combat cancer. “NanoCell is not only championing these scientific advancements but is also committed to ensuring that such life-saving therapies are attainable, adaptable, and broadly disseminated globally, reaching populations that have historically had limited access to medical breakthroughs.”
When asked about the decision to expand NanoCell Therapeutics’ operations to the Netherlands, Maurits Geerlings, highlights the strategic nature of this move. “Our choice of the Netherlands complements our foundation in the US. It offers unique collaborative opportunities, especially in the thriving biotechnology sector. The ease of collaboration between academic groups and the culture of cross-disciplinary innovation here aligns well with our strategy.”
In addition to recognizing the Netherlands’ conducive business environment, Geerlings appreciates the collaborative spirit the country fosters, which complements the innovation-driven culture of U.S. companies. “The Netherlands provides a supportive platform for growth, asking how it can serve as a valuable partner to U.S. firms looking to expand their reach. With a robust network of institutions ready to assist with legislation, capital resources, labs, and more, it’s a place where business can thrive alongside the vibrant American entrepreneurial spirit.”
NanoCell’s strategic expansion in the Netherlands culminated from an extensive review of premier European biotech regions. “Our search was comprehensive, spanning major innovation centers across Europe. It was the Netherlands’ unique ecosystem that matched our criteria,” states Geerlings.
NanoCell sought a location that fostered growth with streamlined operations and strong intellectual property protections, along with access to a diverse pool of scientific expertise. “The Netherlands excelled, particularly Utrecht, offering a rare blend of business-friendly policies, strategic positioning, and a significant pool of interdisciplinary talent.” he adds. “Moreover, the expertise and collaboration of our Utrecht-based team highlight the region’s solid scientific capabilities.”
NanoCell Therapeutics has laid down roots in the Netherlands, already boasting a local team of 12 and plans for further expansion, including additional laboratory space. The company’s commitment to the Utrecht Science Park is underscored by its strategic advantages. “Our preference is to deepen our presence within the Utrecht Science Park,” Geerlings remarks. “The proximity to key medical and research institutions like the University Medical Center, Utrecht University, and the Princess Maxima Hospital facilitates a collaborative environment that is essential for innovation.”
Geerlings is optimistic about the future, seeing NanoCell as a part of the larger narrative of the Netherlands’ inviting ecosystem for pioneering biotech firms. “With our base here, we are well-positioned to make significant strides in healthcare innovation, benefiting not just the local economy but also contributing to global advancements in biotechnology.”
